Novo Nordisk Looks Ahead After Tresiba Setback, Bets Against Biosimilars
Executive Summary
The Danish pharma is focused on the latest formulation technology for insulin and GLP-1 and combinations thereof to sustain its diabetes market leader position. It’s not particularly worried about biosimilars, despite two of its top sellers coming off-patent in the next few years.